Nov 16, 2019: USFDA approved Zydus Cadila’s Apremilast tablets for the treatment of psoriatic arthritis and moderate to severe plaque psoriasis. The US health regulator to market generic to market the tablets in the strengths of 10 mg, 20 mg, and 30 mg. https://zyduscadila.com/
New antibacterial drug approved by FDA to treat complicated urinary tract infections for antimicrobial resistance
Nov 14, 2019: The U.S. Food and Drug Administration (FDA) approved Shionogi’s Fetroja (cefiderocol), an antibacterial drug used for the patients of 18 years of age or older with complicated urinary tract infections (cUTI), also kidney infections caused by susceptible Gram-negative microorganisms.
Patients known history of severe hypersensitivity to beta-lactam antibacterial drugs are restricted to use this drug. https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts
